- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Eosinophilic oesophagitis (EoE)
- Meeting Date: November 2021
- Public Summary Document (PSD) November 2021 PBAC Meeting - (PDF 601KB)
- Public Summary Document (PSD) November 2021 PBAC Meeting - (Word 97KB)
Budesonide – November 2021
Budesonide: Tablet (orally disintegrating) 0.5 mg Tablet (orally disintegrating) 1 mg; Jorveza®
Last updated
4 August 2022